TFS HealthScience Acquires Appletree CI Group, Expanding Expertise in Ophthalmology and Medical Devices for Improved Patient Impact

LUND, Sweden, Jan. 23, 2023 /PRNewswire/ -- Today, TFS HealthScience, a global contract research organization, announced a strategic acquisition of Appletree CI Group to enhance the company's existing expertise in the complex fields of ophthalmology, dermatology, medical devices, and pediatric studies, simultaneously expanding geographic reach for clients.

TFS HealthScience Acquires Appletree, Expands Expertise in Ophthalmology and Medical Devices for Improved Patient ImpactOphthalmology is a rapidly growing field of medicine, with novel innovations and cutting-edge treatments for sight-threatening diseases. A recent study published in The Journal of American Medicine found a 203% increase in funding for ophthalmology research from 2014 to 2020. Additionally, the worldwide ophthalmology drug market is expected to reach $60.3 billion by 2028, an increase of 6.4% from 2021 figures. "We are proud to partner with Appletree as we continue to provide our clients with in-depth, comprehensive knowledge and therapeutic expertise, particularly in the field of ophthalmology," said CEO of TFS HealthScience, Bassem Saleh. "This acquisition, and others in the pipeline, are a clear indicator of the growth and success of TFS. The partnership with Appletree will have a measurable impact on better treatments for patients and company growth, establishing a new presence in Switzerland and additional presence in Poland, Belgium, Hungary, and the U.K."The strategic acquisition of Appletree will complement TFS HealthScience's mission to be a market leader in ophthalmology research. In a targeted business shift toward ophthalmology expertise, the company launched its elite site network initiative and site liaison services, which will shift the industry's approach to ophthalmology clinical trial delivery.